The Managed Care Biologics & Injectables Index (MCBII) is the largest and longest running quantitative report focused on Issues of Access to specialty products. It is a syndicated report based on quarterly multi-stakeholder surveys and is meant to provide a comprehensive view of the current and anticipated impact of various market dynamics across multiple specialty non-oncology therapeutic areas.
Make informed and smart strategy recommendations with robust, market-representative research on specialty therapies
Estimate multi-stakeholder clinical value perception and anticipated adoption of upcoming pipeline agents
Use a combination of quantitative and qualitative insights to design techniques ensuring your brand’s competitiveness in categories expanding with new agents
Bridge the gap between custom and syndicated research by providing input into surveys and receiving a tailored view of the syndicated findings
Develop Payer profiles to predict future policy development and management changes
This syndicated report is customizable to the requirements of various departments. Additionally, the service-based model of this product ensures not just actionable data, but the accompanying expertise of our team to help your organization with informed strategic decisions.